Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults
Open Access
- 30 September 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (9) , e25398
Abstract
Typhoid fever causes more than 21 million cases of disease and 200,000 deaths yearly worldwide, with more than 90% of the disease burden being reported from Asia. Epidemiological data show high disease incidence in young children and suggest that immunization programs should target children below two years of age: this is not possible with available vaccines. The Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM197) for infant vaccination concomitantly with EPI vaccines, either starting at 6 weeks with DTP or at 9 months with measles vaccine. We report the results from a Phase 1 and a Phase 2 dose ranging trial with Vi-CRM197 in European adults. Following randomized blinded comparison of single vaccination with either Vi-CRM197 or licensed polysaccharide vaccines (both containing 25·0 µg of Vi antigen), a randomised observer blinded dose ranging trial was performed in the same center to compare three concentrations of Vi-CRM197 (1·25 µg, 5·0 µg and 12·5 µg of Vi antigen) with the polysaccharide vaccine. All vaccines were well tolerated. Compared to the polysaccharide vaccine, Vi-CRM197 induced a higher incidence of mild to moderate short lasting local pain. All Vi-CRM197 formulations induced higher Vi antibody levels compared to licensed control, with clear dose response relationship. Vi-CRM197 did not elicit safety concerns, was highly immunogenic and is therefore suitable for further clinical testing in endemic populations of South Asia. ClinicalTrials.gov NCT01123941 NCT01193907Keywords
This publication has 21 references indexed in Scilit:
- The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant VaccinesClinical and Vaccine Immunology, 2011
- Evaluation of the Immunogenicity and Biological Activity of the Citrobacter freundii Vi-CRM 197 Conjugate as a Vaccine for Salmonella enterica Serovar TyphiClinical and Vaccine Immunology, 2011
- Aims and role of Novartis Vaccines Institute for Global Health (NVGH)Procedia in Vaccinology, 2010
- A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in IndiaNew England Journal of Medicine, 2009
- a study of typhoid fever in five Asian countries: disease burden and implications for controlsBulletin of the World Health Organization, 2008
- Bacteremic Typhoid Fever in Children in an Urban Slum, BangladeshEmerging Infectious Diseases, 2005
- Effect of Dosage on Immunogenicity of a Vi Conjugate Vaccine Injected Twice into 2- to 5-Year-Old Vietnamese ChildrenInfection and Immunity, 2004
- The Efficacy of aSalmonella typhiVi Conjugate Vaccine in Two-to-Five-Year-Old ChildrenNew England Journal of Medicine, 2001
- Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunizationVaccine, 1996
- Prevention of Typhoid Fever in Nepal with the VI Capsular Polysaccharide ofSalmonella TyphiNew England Journal of Medicine, 1987